Table 3. Literature based classification of PR- and PS-specific hubs.

Alterations in cancers (high expression, mutation, and translocation)
Cancer	High expression (or gene amplification)	Mutation (and/or polymorphism)	Translocation	Diverse
Lymphoma	TOP2A[78, 79], BCL11A[80], BCL11B[81], and PLCG2[82]	PLCG1[83]	BCL11A[84]	BCL11B[85]
Other cancers	AXIN2[86, 87], NLK[88], TOP2A[89], HDAC1 & HDAC2[90], BCL11A[80, 84], BCL11B[85, 91], EHMT2[92], FZD6[93, 94], PLCG2[82], PLCG[95, 96], GRM5[97, 98], and GRAP2[99]	AXIN2[86], CAMKK1[100], CEP72[101]*, GRIN2D[102, 103], and GRIN2B[70]	BCL11A[84] and BCL11B[91]	CKAP5[104], CHD5[105–108], GRIN2B[109], and CACNA2D3[110, 111]

Hubs were grouped based on their alterations in lymphoma and/or other cancers. The diverse group refers to the alterations other than overexpression, mutation, and translocation. PR- and PS-specific hubs are presented in bold and italic, respectively.

*Polymorphism in promoter region.